German recommendations for diagnosis and treatment of breast cancer 2008. What is new from the breast commission of the German gynaecological oncology working group (AGO)?

Breast Care

Volumn 3, Issue 2, 2008, Pages 93-99

  Kantelhardt, Eva J ^a   Thomssen, Christoph ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Breast cancer; Diagnostics; Recommendations; Treatment

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FLUOXETINE; LAPATINIB; LETROZOLE; PACLITAXEL; PAROXETINE; RAZOXANE; TAMOXIFEN; TRASTUZUMAB; VENLAFAXINE;

BONE METASTASIS; BREAST CANCER; BREAST SARCOMA; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; EVIDENCE BASED MEDICINE; GERMANY; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MASTECTOMY; PAGET BONE DISEASE; PLASTIC SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT DURATION;

EID: 44949122590     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000127441     Document Type: Review

References (12)

1. www.ago-online.de.
2. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
3. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
4. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. V.I.2008; www.nccn.org.
5. Oxford Centre for Evidence based Medicine: Levels of Evidence, May 2001. www.cebm.net/levels_of_evidence.asp, Oxford_CEBM_Levels_5[1].rtf.
6. Aktuelle Empfehlungen zur Therapie Primärer und Fortgeschrittener Mammakarzinome, Hrsg. Kommission Mamma vertreten durch Prof. Thomssen. München, Zuckschwerdt , 2007.
7. www.krebsgesellschaft.de.
8. www.adjuvantonline.com.
9. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
10. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53.
11. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
12. Cordeiro PG, McCarthy CM: A single surgeon's 12-year experience with tissue expander/implant reconstruction: part I. A prospective analysis of early complications. Part II. An analysis of long-term complications, aesthetic outcomes, and patients satisfaction. Plast Reconstr Surg 2006;118:825-39.